Roche Partners with 10 Govt Hospitals to Strengthen Clinical Trial Capabilities in India
Chennai: Roche Pharma India has announced the successful completion of the first phase of its Advanced Inclusive Research (AIR) Site Alliance initiative in India. The initiative partnered with 10 leading government hospitals from across the country to strengthen clinical trial capabilities and trained nearly 400 professionals to global Good Clinical Practice (GCP) standards.
Strengthening India’s Role in Global Clinical Research
The partnership aims to enable faster patient access to breakthrough therapies and ensure India’s diverse population is better represented in clinical research. The project aligns with India’s national priorities, including the CDSCO’s encouragement for greater participation of government sites in Phase 3 and 4 trials and the Pharmaceutical Research and Innovation Policy (PRIP) initiative.
Participating Hospitals
The 10 participating hospitals include:
- AIIMS, Rishikesh
- Safdarjung Hospital, New Delhi
- PGIMS, Rohtak
- Homi Bhabha Cancer Hospital & Research Center, Muzaffarpur
- Balco Medical Centre, Raipur
- Government Medical College, Aurangabad
- Indira Gandhi Institute of Child Health, Bengaluru
- Dr. Bhubaneswar Borooah Cancer Institute (BBCI), Guwahati
- Kalyan Singh Super Speciality Cancer Institute & Hospital, Lucknow
- Acharya Harihar Post Graduate Institute of Cancer, Cuttack
A Step towards Building Equitable Healthcare
According to Dr. Sivabalan Sivanesan, Country Medical Director, Roche Pharma India, “By equipping leading government hospitals with global-standard clinical trial capabilities, we are helping to bring innovations faster to India. This is a crucial step toward building equitable healthcare and shaping treatments that are relevant for India.”
Expert Insights
Dr. Amit Sehrawat, Associate Professor, Medical Oncology & Hematology, AIIMS, Rishikesh, and Dr. Vyunkta Raju K N, Professor, Dept of Paediatric Neurology, Indira Gandhi Institute of Child Health, praised the initiative, highlighting its potential to accelerate capacity-building and strengthen India’s clinical research ecosystem.
